See more : Urbana Corporation (URB-A.CN) Income Statement Analysis – Financial Results
Complete financial analysis of TELA Bio, Inc. (TELA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TELA Bio, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Caliber Imaging & Diagnostics, Inc. (LCDX) Income Statement Analysis – Financial Results
- Guangzhou Sanfu New Materials Technology Co.,Ltd (688359.SS) Income Statement Analysis – Financial Results
- CSL Limited (CSL.AX) Income Statement Analysis – Financial Results
- Haydale Graphene Industries plc (HDGHF) Income Statement Analysis – Financial Results
- Universal Technical Institute, Inc. (UTI) Income Statement Analysis – Financial Results
TELA Bio, Inc. (TELA)
About TELA Bio, Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 58.45M | 41.42M | 29.46M | 18.21M | 15.45M | 8.27M | 4.25M |
| Cost of Revenue | 18.34M | 14.37M | 10.65M | 6.98M | 6.17M | 5.33M | 1.71M |
| Gross Profit | 40.11M | 27.04M | 18.81M | 11.23M | 9.27M | 2.94M | 2.53M |
| Gross Profit Ratio | 68.62% | 65.30% | 63.85% | 61.68% | 60.03% | 35.56% | 59.65% |
| Research & Development | 9.62M | 8.94M | 6.74M | 4.26M | 4.15M | 4.34M | 5.79M |
| General & Administrative | 14.89M | 13.86M | 12.46M | 10.14M | 6.22M | 4.90M | 4.96M |
| Selling & Marketing | 59.68M | 43.25M | 29.06M | 22.11M | 18.06M | 13.65M | 8.71M |
| SG&A | 74.57M | 57.11M | 41.52M | 32.25M | 24.28M | 18.55M | 13.67M |
| Other Expenses | 0.00 | -10.00K | -228.00K | 45.00K | 351.00K | 70.00K | 94.00K |
| Operating Expenses | 84.19M | 66.05M | 48.26M | 36.51M | 28.43M | 22.88M | 19.46M |
| Cost & Expenses | 102.53M | 80.43M | 58.91M | 43.49M | 34.61M | 28.22M | 21.17M |
| Interest Income | 0.00 | 4.05M | 3.60M | 3.56M | 3.61M | 0.00 | 0.00 |
| Interest Expense | 5.22M | 4.05M | 3.60M | 3.56M | 3.61M | 1.80M | 4.56M |
| Depreciation & Amortization | 808.00K | 1.19M | 535.00K | 525.00K | 582.00K | 1.25M | 761.00K |
| EBITDA | -40.63M | -39.06M | -29.14M | -24.71M | -18.23M | -18.04M | -16.02M |
| EBITDA Ratio | -69.51% | -94.20% | -100.73% | -138.53% | -121.79% | -225.09% | -378.54% |
| Operating Income | -44.08M | -39.01M | -29.45M | -25.28M | -19.16M | -17.78M | -16.92M |
| Operating Income Ratio | -75.40% | -94.18% | -99.96% | -138.77% | -124.06% | -214.91% | -398.68% |
| Total Other Income/Expenses | -2.59M | -5.29M | -3.83M | -3.52M | -3.26M | -3.31M | -4.41M |
| Income Before Tax | -46.66M | -44.30M | -33.28M | -28.79M | -22.43M | -21.09M | -21.33M |
| Income Before Tax Ratio | -79.83% | -106.95% | -112.94% | -158.10% | -145.18% | -254.92% | -502.57% |
| Income Tax Expense | 0.00 | 41.00K | 2.83M | 3.08M | 3.38M | -1.51M | 4.65M |
| Net Income | -46.66M | -44.34M | -36.11M | -31.88M | -25.80M | -21.09M | -21.33M |
| Net Income Ratio | -79.83% | -107.05% | -122.56% | -175.03% | -167.05% | -254.92% | -502.57% |
| EPS | -2.04 | -2.73 | -2.49 | -2.46 | -2.26 | -3.25 | -3.29 |
| EPS Diluted | -2.04 | -2.73 | -2.49 | -2.46 | -2.26 | -3.25 | -3.29 |
| Weighted Avg Shares Out | 22.87M | 16.27M | 14.47M | 12.93M | 11.41M | 6.49M | 6.49M |
| Weighted Avg Shares Out (Dil) | 22.87M | 16.27M | 14.47M | 12.93M | 11.41M | 6.49M | 6.49M |
TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy
Howard N. Langstein, MD, FACS joins innovative MedTech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgery Howard N. Langstein, MD, FACS joins innovative MedTech company to leverage his vast experience...
TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript
TELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcript
TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.52 per share a year ago.
TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results
MALVERN, Pa., March 21, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy,...
TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery
Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue
TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX
TELA Bio to receive at least $8 million and up to $12 million in total consideration TELA Bio to receive at least $8 million and up to $12 million in total consideration
TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results
MALVERN, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Feb. 23, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Jan. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's...
TELA Bio: Looks Like A Buy, But Some Pieces Missing To Make This A Strong Buy
OviTex sales continue to see strong annual growth. However, before being able to conclusively say that OviTex is better than competitors, some head-to-head data is needed. The liquidity position is not great, and dilution seems likely.
Source: https://incomestatements.info
Category: Stock Reports